Literature DB >> 25815852

Cancer cachexia, recent advances, and future directions.

Marie-France Penet1, Zaver M Bhujwalla.   

Abstract

Cancer cachexia is defined as a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass with or without loss of fat mass. The syndrome cannot be fully reversed by conventional nutritional support, and despite an increased number of studies related to cancer cachexia, the underlying mechanisms are still poorly defined, and therapeutic options are limited. This review focuses on recent studies investigating mechanisms and pathways in cancer cachexia. The role of molecular and functional imaging in identifying cachexia at an earlier stage, in identifying potential metabolic targets and pathways, and in assessing treatment efficacy is also reviewed.

Entities:  

Mesh:

Year:  2015        PMID: 25815852      PMCID: PMC4910156          DOI: 10.1097/PPO.0000000000000100

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  34 in total

1.  Metabolic signatures imaged in cancer-induced cachexia.

Authors:  Marie-France Penet; Mayur M Gadiya; Balaji Krishnamachary; Sridhar Nimmagadda; Martin G Pomper; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

2.  Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.

Authors:  Xiaolan Zhou; Jin Lin Wang; John Lu; Yanping Song; Keith S Kwak; Qingsheng Jiao; Robert Rosenfeld; Qing Chen; Thomas Boone; W Scott Simonet; David L Lacey; Alfred L Goldberg; H Q Han
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

3.  Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia.

Authors:  Calum Gray; Thomas J MacGillivray; Clare Eeley; Nathan A Stephens; Ian Beggs; Kenneth C Fearon; Carolyn A Greig
Journal:  Clin Nutr       Date:  2010-08-19       Impact factor: 7.324

4.  Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia.

Authors:  Marc-André Weber; Holger Krakowski-Roosen; Leif Schröder; Ralf Kinscherf; Martin Krix; Annette Kopp-Schneider; Marco Essig; Peter Bachert; Hans-Ulrich Kauczor; Wulf Hildebrandt
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

5.  Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.

Authors:  C A Greig; N Johns; C Gray; A MacDonald; N A Stephens; R J E Skipworth; M Fallon; L Wall; G M Fox; K C H Fearon
Journal:  Support Care Cancer       Date:  2014-01-04       Impact factor: 3.603

6.  The hunger hormone ghrelin in cachexia.

Authors:  Alessio Molfino; Gianfranco Gioia; Maurizio Muscaritoli
Journal:  Expert Opin Biol Ther       Date:  2013-01-07       Impact factor: 4.388

7.  Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia.

Authors:  F G Shellock; M S Riedinger; M C Fishbein
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

8.  Pancreatic cancer-induced cachexia is Jak2-dependent in mice.

Authors:  Marine Gilabert; Ezequiel Calvo; Ana Airoldi; Tewfik Hamidi; Vincent Moutardier; Olivier Turrini; Juan Iovanna
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

9.  Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile.

Authors:  Claudio Pietra; Yasuhiro Takeda; Naoko Tazawa-Ogata; Masashi Minami; Xia Yuanfeng; Elizabeth Manning Duus; Robert Northrup
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-09-30       Impact factor: 12.910

10.  Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

Authors:  David R Fogelman; Holly Holmes; Khalil Mohammed; Matthew H G Katz; Carla M Prado; Jessica Lieffers; Naveen Garg; Gauri R Varadhachary; Rachna Shroff; Michael J Overman; Christopher Garrett; Robert A Wolff; Milind Javle
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-04-17       Impact factor: 12.910

View more
  27 in total

1.  Wasting away: How to treat cachexia and muscle wasting in chronic disease?

Authors:  Stephan von Haehling
Journal:  Br J Clin Pharmacol       Date:  2017-08-24       Impact factor: 4.335

2.  Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss.

Authors:  Lorena Lerner; Jeno Gyuris; Richard Nicoletti; James Gifford; Brian Krieger; Aminah Jatoi
Journal:  Oncol Lett       Date:  2016-09-23       Impact factor: 2.967

Review 3.  Update on Management of Cancer-Related Cachexia.

Authors:  Lindsey J Anderson; Eliette D Albrecht; Jose M Garcia
Journal:  Curr Oncol Rep       Date:  2017-01       Impact factor: 5.075

4.  Validation of the Chinese version of functional assessment of anorexia-cachexia therapy (FAACT) scale for measuring quality of life in cancer patients with cachexia.

Authors:  Ting Zhou; Kaixiang Yang; Sudip Thapa; Qiang Fu; Yongsheng Jiang; Shiying Yu
Journal:  Support Care Cancer       Date:  2016-11-29       Impact factor: 3.603

Review 5.  Pancreatic cancer: branched-chain amino acids as putative key metabolic regulators?

Authors:  Lenka Rossmeislová; Jan Gojda; Katarína Smolková
Journal:  Cancer Metastasis Rev       Date:  2021-12-28       Impact factor: 9.264

Review 6.  The role of adipose tissue in cancer-associated cachexia.

Authors:  Janina A Vaitkus; Francesco S Celi
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-08

7.  Evaluating the Demand for Integrative Medicine Practices in Breast and Gynecological Cancer Patients.

Authors:  Nikolas Schuerger; Evelyn Klein; Alexander Hapfelmeier; Marion Kiechle; Christine Brambs; Daniela Paepke
Journal:  Breast Care (Basel)       Date:  2018-10-23       Impact factor: 2.860

8.  Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy.

Authors:  Takashi Kokumai; Shuichi Aoki; Masamichi Mizuma; Shimpei Maeda; Hideo Ohtsuka; Kei Nakagawa; Takanori Morikawa; Fuyuhiko Motoi; Takashi Kamei; Michiaki Unno
Journal:  Surg Today       Date:  2021-04-07       Impact factor: 2.549

9.  Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia.

Authors:  Ji-Hyung Lee; Seon-Wook Kim; Jun-Hyeong Kim; Hyun-Jun Kim; JungIn Um; Da-Woon Jung; Darren R Williams
Journal:  Cells       Date:  2021-04-26       Impact factor: 6.600

10.  Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage.

Authors:  George Stojan; Jessica Li; Amaya Wittmaack; Michelle Petri
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-10-07       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.